Answers are grounded in this paper and cite their sources.
Demonstrates response to therapy in lung tumor models, suggesting utility for testing treatment outcomes and biomarkers.
Novel preclinical models that better mimic the in vivo tumor microenvironment are essential to advance understanding of tumor biology and resistance/response to therapy. Herein, we report development of a novel ex vivo patient-derived three-dimensional lung tumor model (3D-LTM) for use in evaluating response to therapy. With this model system that maintains cell-cell interactions and tissue architecture, we observed heterogeneity of response to immune checkpoint inhibitors (ICI), as noted in non-small cell lung cancer (NSCLC) patients, and defined gene signatures associated with response. Spatial transcriptomics identified positive correlation of CD8 + T cell populations, CD4 + memory T cells, mast cells, NK cells, naive B cells, endothelial cells and non-classical monocytes with response status, and negative correlation of macrophages with response status. Pathway analysis of gene expression showed that chemokine signaling related pathways were activated in responder 3D-LTM tissues, whereas suppression of antigen presentation-related pathways and activation of T reg differentiation-related pathways were associated with non-responder 3D-LTM tissues. Additionally, the abundance of dividing T cells and naive CD8 + T cells differentially correlated with T cell cytotoxicity gene signatures based on response status. Thus, this model may provide utility for rapid testing of therapeutic outcomes and biomarker development.
No takes yet. Share an insight, caveat, or question.
Goliwas et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: